Feedback / Questions
OT-C001 - Onward Therap
https://www.newswire.ca/news-releases/onward-therapeutics-announces-impd-approval-for-its-subsidiary-emercell-to-start-clinical-investigation-of-allogeneic-nk-cell-therapy-ot-c001-in-combination-with-rituximab-831246195.html
Apr 22, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next